Cardiology · Clinical Calculator · Acute Coronary Syndrome

TIMI Risk Score Unstable Angina / NSTEMI

The TIMI (Thrombolysis In Myocardial Infarction) risk score sums seven dichotomous (0 or 1) items in a patient with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). The total (0–7) estimates the 14-day composite of all-cause mortality, new or recurrent myocardial infarction, and severe recurrent ischemia prompting urgent revascularization — and higher scores identify the patients who derive the greatest benefit from low-molecular-weight heparin (LMWH) and from an early invasive strategy.

Published: References: 1 Read time:

← All calculators & tools  ·  HEART Score →

Instructions
  1. Apply to an adult with unstable angina or non-ST-elevation myocardial infarction after an initial 12-lead EKG and cardiac biomarker (troponin or CK-MB) have been obtained.
  2. Check each of the seven items that is present (worth 1 point each). Leave unchecked boxes as absent (0 points).
  3. The total TIMI Risk Score is 0–7. The 14-day composite risk (all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia prompting urgent revascularization) updates automatically.
  4. Higher scores identify patients who derive greater benefit from low-molecular-weight heparin (TIMI 11B / ESSENCE) and from an early invasive strategy (TACTICS-TIMI 18).

All computation runs in your browser; no values are stored or transmitted.

When to Use

Use the TIMI Risk Score in adults with confirmed or strongly suspected unstable angina or NSTEMI to quantify short-term (14-day) risk of death, new or recurrent myocardial infarction, or severe recurrent ischemia requiring urgent revascularization. It was derived in the TIMI 11B and ESSENCE trials and is most helpful when deciding between an early invasive and a more conservative management strategy.

✅

Appropriate population

Adults with unstable angina or NSTEMI who have undergone an initial EKG and cardiac biomarker assay. The score has been validated across multiple acute coronary syndrome cohorts and remains a standard risk-stratification tool in combination with current guideline-directed care.

⚠️

When NOT to rely on it

Do not apply to patients with ST-elevation myocardial infarction (STEMI) — use the TIMI STEMI score instead. For undifferentiated chest pain in the emergency department (acute coronary syndrome not yet established), the HEART Score was derived for that specific setting and performs better. For in-hospital or 6-month mortality in confirmed acute coronary syndrome, the GRACE score has broader calibration. TIMI does not substitute for current serial troponin trajectories or hemodynamic and electrical risk assessment.

Pearls & Pitfalls
💡

Treatment benefit tracks the score

In TIMI 11B and ESSENCE, enoxaparin outperformed unfractionated heparin most clearly as the TIMI Risk Score rose above 2. In TACTICS-TIMI 18, the early invasive strategy produced the greatest absolute benefit in moderate-to-high-risk patients (scores ≥ 3). The score is not just prognostic — it identifies the group most likely to be helped by escalation.

🔬

Count risk factors carefully

The "≥ 3 CAD risk factors" item counts hypertension, hypercholesterolemia, diabetes mellitus, current cigarette smoking, and family history of premature coronary artery disease. A documented personal history of coronary disease is a separate item ("Known CAD: prior coronary stenosis ≥ 50%"). Do not double-count.

🚫

Pitfalls

(1) The score is dichotomous — a single ST-segment deviation of 0.5 mm counts the same as marked ST depression. Always interpret with the EKG itself. (2) "Severe angina" means at least two anginal episodes in the preceding 24 hours; one episode does not count. (3) The score does not adjust for renal function, heart failure, or hemodynamic instability — these are powerful modifiers that the GRACE score captures better. (4) The 14-day event rates below are from the TIMI 11B derivation cohort and should be interpreted alongside contemporary care (dual antiplatelet therapy, high-intensity statin, early invasive strategy as indicated), which lowers absolute event rates.

Why Use It

The TIMI Risk Score for unstable angina/NSTEMI, derived by Antman and colleagues in the TIMI 11B and ESSENCE enoxaparin trials, is one of the oldest and best-studied acute coronary syndrome risk scores. Its strengths are its simplicity (seven dichotomous items, computable at the bedside in seconds) and its decision utility: the score has been shown in randomized data to identify the patients who benefit most from low-molecular-weight heparin over unfractionated heparin and from an early invasive strategy over conservative management. It remains a common risk-stratification tool in acute coronary syndrome guidelines and in internal medicine training, though it is now typically used alongside, rather than instead of, the GRACE score and current serial troponin strategies.

TIMI Risk Score — Unstable Angina / NSTEMI

Check each item that is present. The total TIMI Risk Score (0–7), the 14-day composite event rate, and treatment-benefit guidance update automatically.

e.g. 72 — Chronologic age at presentation.
e.g. yes — Count hypertension, hypercholesterolemia, diabetes, current smoking, and family history of premature coronary artery disease.
e.g. yes — Documented angiographic coronary stenosis ≥ 50%, prior myocardial infarction, prior percutaneous coronary intervention, or prior coronary artery bypass graft.
e.g. yes — Any aspirin exposure in the 7 days before presentation.
e.g. yes — At least two distinct episodes of angina within the 24 hours before presentation.
e.g. yes — ST-segment depression or transient elevation ≥ 0.5 mm on the presenting 12-lead EKG.
e.g. yes — Any cardiac troponin above the 99th-percentile upper reference limit, or elevated CK-MB.
0
TIMI Score
0 – 7
4.7%
14-day composite
Antman 2000
Low
Risk Band
score 0 – 1

⚕ Antman EM, Cohen M, Bernink PJLM, et al. JAMA. 2000;284(7):835–842. The 14-day composite endpoint is all-cause mortality, new or recurrent myocardial infarction, and severe recurrent ischemia prompting urgent revascularization, from the TIMI 11B derivation cohort. For licensed clinicians; not a substitute for individualized assessment.

Next Steps

Use the TIMI Risk Score to classify short-term risk, choose antithrombotic therapy, and time coronary angiography.

  • Low score (0 – 2): 14-day composite 4.7% (score 0–1) to 8.3% (score 2). A conservative, ischemia-guided strategy is reasonable in most of these patients; continue dual antiplatelet therapy and anticoagulation and reassess with serial troponins.
  • Moderate score (3 – 4): 14-day composite 13.2% to 19.9%. Both TIMI 11B/ESSENCE (low-molecular-weight heparin over unfractionated heparin) and TACTICS-TIMI 18 (early invasive strategy) showed substantial benefit at this risk level.
  • High score (5 – 7): 14-day composite 26.2% to 40.9%. Early invasive strategy (angiography within 24 – 48 hours) is strongly favored; prioritize guideline-directed acute coronary syndrome therapy and cardiology consultation.
  • Pair this with the GRACE ACS score for in-hospital and 6-month mortality, and the HEART Score for undifferentiated emergency-department chest pain.
Evidence & References

Seven-Item TIMI Risk Score

Item (1 point each if present)
Age ≥ 65 years
≥ 3 coronary artery disease risk factors (hypertension, hypercholesterolemia, diabetes, current smoking, family history of premature coronary artery disease)
Known coronary artery disease (prior stenosis ≥ 50%)
Aspirin use in the prior 7 days
Severe angina (≥ 2 episodes in the preceding 24 hours)
ST deviation ≥ 0.5 mm on the presenting EKG
Positive cardiac biomarkers (troponin or CK-MB)

14-day Composite Event Rate by Score (TIMI 11B)

ScoreMortality, new/recurrent MI, or severe recurrent ischemia with urgent revascularization
0 – 14.7%
28.3%
313.2%
419.9%
526.2%
6 – 740.9%

The composite endpoint was defined in the TIMI 11B trial as all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia prompting urgent revascularization within 14 days. Higher scores predicted greater absolute benefit from enoxaparin over unfractionated heparin in TIMI 11B and ESSENCE, and from an early invasive strategy in TACTICS-TIMI 18.

References

  1. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–842. doi:10.1001/jama.284.7.835.
Important: This calculator is an educational aid for licensed clinicians and does not replace individualized clinical judgment. The TIMI Risk Score for unstable angina/NSTEMI predicts short-term (14-day) composite outcomes in confirmed or strongly suspected acute coronary syndrome; it does not diagnose acute coronary syndrome, does not apply to STEMI, and does not substitute for current serial troponin trajectories, hemodynamic assessment, or local institutional acute coronary syndrome pathways. Always integrate the result with the full clinical assessment, EKG, serial biomarkers, and guideline-directed therapy.
References 1 source
  1. Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000). The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA, 284(7), 835–842. https://doi.org/10.1001/jama.284.7.835
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides